Leukocyte Biology and Inflammation Program, Renal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
In the presence of bound Mn2+, the three- dimensional structure of the ligand-binding A-domain from the integrin CR3 (CD11b/CD18) is shown to exist in the "open" conformation previously described only for a crystalline Mg2+ complex. The open conformation is distinguished from the "closed" form by the solvent exposure of F302, a direct T209-Mn2+ bond, and the presence of a glutamate side chain in the MIDAS site. Approximately 10% of wild-type CD11b A-domain is present in an "active" state (binds to activation-dependent ligands, e.g., iC3b and the mAb 7E3). In the isolated domain and in the holoreceptor, the percentage of the active form can be quantitatively increased or abolished in F302W and T209A mutants, respectively. The iC3b-binding site is located on the MIDAS face and includes conformationally sensitive residues that undergo significant shifts in the open versus closed structures. We suggest that stabilization of the open structure is independent of the nature of the metal ligand and that the open conformation may represent the physiologically active form.
Key words: integrin activation; A-domain; crystal structure; complement iC3b; G proteins ![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE interaction of integrins with their ligands is an
essential step in regulating many cellular functions
(reviewed in Hynes, 1992). Integrin binding to various ligands is divalent cation dependent, and is tightly regulated by inside-out and outside-in signaling events. The
mechanisms through which these signals modulate integrin-ligand interactions are not known. Biophysical, biochemical, and immunochemical studies have revealed that
integrins exist in low and high affinity states (Du et al.,
1993
). Activation signals lead to conformational changes
that extend to the receptor's extracellular ligand-binding
regions (Diamond and Springer, 1993
; Landis et al., 1993
;
Bilsland et al., 1994
; Kamata and Takada, 1994
; Randi and
Hogg, 1994
; Zhou et al., 1994
). It has also been proposed
that rapid oscillations between the low and high affinity states of integrins contribute to the adhesion-deadhesion
cycles during cell migration and cytolysis (Dransfield et
al., 1992
).
Recent studies in several integrins have identified two
major ligand-binding sites. One is located within an A-type
domain (A- or I-domain) present in the subunits of seven
integrins (Diamond et al., 1993
; Michishita et al., 1993
;
Landis et al., 1994
; Randi and Hogg, 1994
; Zhou et al., 1994
;
Tuckwell et al., 1995
; Xie et al., 1995
). A second region is
located in a highly conserved segment of all the integrin
subunits (D'Souza et al., 1988
; Smith and Cheresh, 1988
;
Andrew et al., 1994
; Bajt and Loftus, 1994
; D'Souza et al.,
1994
; Kamata et al., 1995a
). Secondary structure, hydropathy, and protein threading algorithm predict that this segment also adopts an A-type fold (Lee et al., 1995b
; Arnaout, M.A., unpublished observations), suggesting that
structure-function analysis of the A-domain is likely to
shed light on the structural basis of affinity switching in all
integrins.
The recombinant CD11b A-domain (r11bA) from the
2 integrin CR3 (CD11b/CD18,
M
2) binds directly to
several ligands in a divalent cation-dependent manner
(Michishita et al., 1993
; Lee et al., 1995b
). Some of these
ligands (e.g., iC3b, fibrinogen, CD54 [ICAM-1], and the
ligand-mimetic mAb 7E3) can only interact with the holoreceptor in its active state. Others such as neutrophil inhibitory factor (NIF)1 bind to CR3 regardless of its activation status (Michishita et al., 1993
; Rieu et al., 1994
; Ueda
et al., 1994
; Zhou et al., 1994
; Lee et al., 1995b
; Xie et al.,
1995
). The ability of both activation-dependent and -independent ligands to bind to r11bA suggests that the r11bA
either becomes active when removed from the holoreceptor or exists in different affinity states. The crystal structures of several integrin A-domains have been published. The structures invariably include a dinucleotide-binding
fold (similar to that of small G proteins where the fold was
first described), a buried
sheet surrounded by amphipathic helices (seven in CD11b A-domain), and a solvent-exposed metal ion located in a crevice at the COOH-terminal end of the
sheet. The metal ion is coordinated by a
group of conserved amino acids forming the metal ion-
dependent adhesion site (MIDAS). The first published structure of r11bA complexed to Mg2+ (Lee et al., 1995b
)
("open" form) showed significant differences from a second "closed" conformation of r11bA complexed to Mn2+
(Lee et al., 1995a
; Baldwin et al., 1998
) and from all
CD11a crystal structures (Qu and Leahy, 1995
): in the
open form, a glutamate from a neighboring molecule
provides the sixth metal coordination site. In addition, two
phenylalanines (F275 and F302) are solvent exposed due
to conformational changes that involve several loops. Based on mechanistic similarities with the "active" and
"inactive" structures of the signaling proteins ras and G
,
we suggested that this open form is active while the closed
conformation is inactive (Lee et al., 1995a
). Because the
open and closed states of r11bA formed in the presence of
different metal ions (Mg2+ and Mn2+, respectively) and
because of the uniformly activating effect of Mn2+ on integrins, a counterargument was made that the Mn2+-complexed form represents the active species (Qu and Leahy,
1995
). More recently, it was argued based on theoretical
considerations that the open form is a structural artifact
that arises secondary to a truncated COOH terminus
(Baldwin et al., 1998
).
In this communication, we demonstrate that r11bA crystallized in the presence of Mn2+ can also assume the open conformation, indicating that generation of this structure is independent of the nature of the metal ion. The functional relevance of the structural changes observed between the open and the closed conformations (changes in MIDAS topology, solvent exposure of F302 and F275, and coordination of the metal ion to T209) was probed through mapping of the iC3b-binding site and by mutational analysis of certain conformationally sensitive residues. The binding site in CR3 for iC3b incorporates conformationally sensitive residues that move up to 3.5 Å in the two structures (relative to the bound manganese metal ion). F302W and F275R substitutions that introduce bulky or charged residues at these two positions, respectively, increased r11bA (and holoreceptor) binding to activation-dependent ligands. On the other hand, a T209A substitution, intended to abolish the direct T209-metal coordination found in the open form, resulted in a complete loss of r11bA (and holoreceptor) binding to activation-dependent ligands. However, none of these mutants affected the interaction of r11bA or the holoreceptor with the activation-independent ligand NIF. Analysis of the interaction of wild-type (WT) r11bA with iC3b using surface plasmon resonance identified active and inactive populations of the A-domain, with the latter predominating. The proportion of the active form increased by 2.5-fold in the F302W domain compared with WT and disappeared by the T209A substitution. We suggest that the active and inactive states may correspond to the open and closed crystal structures, respectively.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Reagents and Antibodies
Restriction and modification enzymes were purchased from New England
Biolabs Inc. (Beverly, MA), Boehringer Mannheim (Mannheim, Germany), or GIBCO BRL (Gaithersburg, MD). The anti-CD11b mAbs OKM10, 44, 903, 904, 7E3, and the anti-CD18 mAb TS1/18 have been described previously (Arnaout et al., 1983; Coller, 1985
; Dana et al., 1986
;
Wright et al., 1987
). Purified fibrinogen was a kind gift from Dr. Jari
Ylanne (University of Helsinki, Helsinki, Finland). mAb 7E3 and FITC-conjugated 7E3 were gifts from Dr. Barry S. Coller (Mount Sinai Medical
Center, New York).
Site-directed Mutagenesis
This was carried out in pcDNA3 or H3M expression vectors as described
(Kunkel et al., 1987
; Deng and Nicoloff, 1992
). Some of the primers used
have been published elsewhere (Rieu et al., 1996
). The following additional mutagenic primers were used, each followed by the introduced
unique restriction site: F302R reverse, CTGAATGGTCTTAAGAGCCTCTCTGTTATTCACCTG (AflII); F302W forward, CGTGTTCCAGGTGAATAACTGGGAAGCTTTGAAGACCATTCAGAACC (HindIII); F302Y reverse, CTGAATGGTCTTAAGAGCCTCGTAGTTATT-CACCTG (AflII); F275R reverse, TTGGCGGGATTTCTCGGACC-GTCTGGCATCTCCCACCCC (RsrII); T209A forward, CTGCTTGG-GCGAGCTCACACGGCCACG (SacI); G247A forward, CGGATGG-AGAAAAGTTTGCGGATCCCTTGGGATATGA (BamHI); and P249A forward, GGAGAAAAGTTTGGCGATGCCTTGGGATATGAGGA-CGTCATCCCT (AatII). Each mutation was confirmed by the presence
of the introduced restriction site and by direct DNA sequencing (Sanger
et al., 1977
). The recombinant DNA work used standard protocols (Maniatis et al., 1989
).
Protein Purification and Characterization
Recombinant WT r11bA and its mutants F302W, T209A, and D140GS/
AGA were expressed as GST fusion proteins in Escherichia coli, as described elsewhere (Michishita et al., 1993; Ueda et al., 1994
). cDNA sequencing of the 3' end of the WT and mutant r11bA constructs predicts a
protein that terminates with A318 of CD11b plus the vector sequence
GNSS. The fusion proteins were purified by affinity chromatography on
glutathione-coupled beads, and cleaved with thrombin to release the recombinant A-domains. WT and mutant r11bA were further purified by
ion exchange chromatography on a Mono S HR5/5 column using the
FPLC system (both from Pharmacia, Piscataway, NJ). Analysis of the purified proteins on 12% SDS-PAGE revealed a single band of the expected
size after staining with Coomassie blue (data not shown).
The purified thrombin-cleaved WT r11bA was digested overnight with
immobilized TPCK-trypsin (Pierce, Rockford, IL) as described (Lee et al.,
1995b), and then repurified by gel filtration on a Superdex-75 column. The
NH2 terminus of the trypsin-treated r11bA begins with G127, as determined by protein sequencing. The COOH termini of both thrombin- and
trypsin-treated preparations were sequenced using the Mayo Protein Core
Facility and were found to be identical. Both proteins end with A318 of
the native domain followed by the vector-derived sequences GD (instead
of the predicted N), with the two COOH-terminal serines detected in
lower quantities (data not shown).
The thrombin- and trypsin-treated preparations were also analyzed by
LC-MS using MassLynx software. The measured mass of the thrombin-cleaved protein is 24,235.8 (calculated mass using monoisotopic masses
based on the predicted 212-amino acid peptide is 24,143.5; measured calculated mass [
] = 92.3; expected measured error of +0.02%). The
measured mass of the limited trypsin-cleavage product (beginning with
G127 and ending with GNSS) is 22,383.7 (calculated 22,293.6,
= 90.1).
LC-MS analysis of the tryptic sequence fragments resulting from an exhaustive digest of the thrombin-cleaved A-domain allowed an assignment
of all of the sequence up to R313. By difference, the mass of the COOH-terminal sequence (E314KIFAGNSS) must be 1025.7 (calculated 952.2,
= 73.5), suggesting that a modification in the COOH-terminal sequence (most likely in the vector sequence) is responsible for the larger measured
mass of the domain.
Crystallization
The trypsin-treated r11bA was desalted on a Bio-Gel P-6DG column
(BIO-RAD, Richmond, CA) and concentrated to 16 mg/ml for crystallization using a centricon unit with a 10 K molecular mass cutoff (Amicon
Inc., Beverly, MA). Crystals were grown using the hanging drop vapor diffusion method by mixing equal volumes (5 µl) of protein and reservoir solution (23% polyethylene glycol 8 K, 0.05 M Tris, pH 8.8, 100 mM MnCl2),
at room temperature (modified from Lee et al., 1995b). Crystals started to
form within a week, grew to a typical size of 0.3 mm × 0.05 mm × 0.04 mm
in 3-4 wk, and belonged to the tetragonal space group P43 (Table I).
These crystals are isomorphous with the Mg2+-containing crystals (Lee
et al., 1995b
).
|
Data Collection and Structure Determination
A single crystal was used to collect a 2.7Å resolution data set, at 100 K, on
beamline X25 of the National Synchrotron Light Source at the Brookhaven National Laboratory using a MarResearch imaging plate detector.
Data were processed with DENZO and SCALEPACK (Otwinowski,
1991) to an Rsym of 12.2%. The starting model was the refined 1.8 Å Mg2+
structure (pdb accession code lido) (Lee et al., 1995b
) comprising residues
D132 to K315, with the metal and water molecules removed. The structure was refined using the computer program PROFFT (Finzel, 1987
) to a
final R factor of 19.8% (1.5 sigma cutoff). The final model comprises all
nonhydrogen atoms of residues D132 to K315, 25 water molecules, and
one manganese metal ion. Water molecules were placed and maintained
based on suitable peaks in difference maps, reasonable hydrogen bond arrangements, and refined temperature factors of <35. Five protein residues
have energetically unfavorable phi-psi angles as demonstrated by a Ramachandran plot (Gln163, Thr169, Ser177, Phe184, and Leu206), and include one of the residues also noted in the 1.8Å structure (Ser177). Examination of hydrogen bonding patterns and local interactions suggest
plausible explanations for the unusual geometry of four of the five residues.
COS Cell Transfections
COS M7 simian fibroblastoid cells at 60-70% confluence were transfected
with supercoiled cDNAs encoding WT and mutant CD11b and CD18 as
described (Michishita et al., 1993). Transfected COS cells were grown for
24 h in Iscove's modified Dulbecco's medium (BioWhittaker, Inc., Walkersville, MD) supplemented with 10% FBS, 2 mM glutamine, 50 IU/ml
penicillin and streptomycin at 37°C. Cells were then washed, detached
with 0.1% trypsin-EDTA, and seeded in replicates for 24 h onto 24- or 48-well plates (Costar Corp., Cambridge, MA) or 100-mm petri dishes. Confluent monolayers in 24- or 48-well plates were then used for cell-surface
antigen quantification and ligand-binding studies and those on petri dishes for immunoprecipitation studies.
Heterodimer Formation
This was assessed as described previously (Michishita et al., 1993). Confluent monolayers of transfected COS cells from 100-mm petri dishes were
washed in PBS containing 5 mM EDTA, and each plate was solubilized in
0.5 ml of PBS containing 1% Triton X-100, 2 mM PMSF, 2 mg/ml leupeptin, and 2 mg/ml pepstatin A (Sigma Chemical Co., St. Louis, MO). The
detergent-soluble fraction was harvested after centrifugation and immunoprecipitated using the anti-CD18 mAb TS1/18. Washed immunoprecipitates were separated by SDS-PAGE under reducing conditions
(Laemmli, 1970
) and electroblotted onto Immobilon-P membranes (Millipore Corp., Bedford, MA). After blocking with 10% nonfat milk in PBS,
the membrane was incubated for 1 h with the anti-CD11b mAb 44 (Arnaout et al., 1983
). Detection of proteins was performed using the enhanced chemiluminescence kit from Amersham Corp. (Buckinghamshire, UK).
Generation of CHO Cell Lines Expressing WT and Mutant CR3
The CHO-K1 cell line was maintained in Ham's F12 nutrient mixture
(GIBCO BRL) supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. Transfection of CHO-K1 cells with WT or F302W
CD11b and CD18 cDNA, in pcDNA3/Neo and H3M plasmids, respectively, was performed using the calcium phosphate precipitation method
as described previously (Golenbock et al., 1993
). After 48 h, the medium
was replaced with fresh medium containing 1 mg/ml of G418. The G418-resistant cell population was analyzed for CR3 expression with a FACScan® flow cytometer (Becton Dickinson, Mountain View, CA), and the CD11b and CD18 double-positive cells were enriched by cell sorting. The
CHO cells expressing WT and F302W CR3 were then cloned by limiting
dilution. CHO cells transfected with pcDNA/Neo alone were made and
used as a negative control.
Preparation of Complement iC3b-coated Erythrocytes and Purification of iC3b
Sheep erythrocytes coated with complement iC3b were prepared as described (Michishita et al., 1993). EiC3b (1.5 × 108 cells/ml) were labeled
with 5-(and-6)-carboxy fluorescein (Molecular Probes, Eugene, OR)
(Ueda et al., 1994
), washed, and resuspended to the original concentration
for use in the binding studies. In some experiments, EiC3b cells were surface labeled with biotin by incubating the cells with 0.5 mg/ml sulfo-NHS-biotin (Pierce) for 30 min at 4°C.
iC3b was purified from fresh human serum by affinity chromatography
as described (Ross et al., 1987; Cai and Wright, 1995
). In brief, 50 ml human serum was treated with 20 mM iodoacetamide (Sigma) to block all
free sulfhydryl groups. After extensive dialysis, the serum was incubated
with 2-3 g of activated thiol-Sepharose 4B (Sigma) for 2 h at 37°C. The
Sepharose activates the complement cascade, and the C3 is captured by
thiol-Sepharose through its newly generated free sulfhydryl group. iC3b
was eluted with 10 mM L-cysteine and further purified by ion exchange
chromatography on a Mono Q HR5/5 column using FPLC system (both
from Pharmacia). The purity of iC3b was examined on 8% SDS-PAGE.
mAb and Ligand Binding to WT or Mutant CR3-transfected COS and CHO Cells
Binding of mAbs, biotinylated NIF, or EiC3b to COS cells was assessed simultaneously as described (Michishita et al., 1993; Rieu et al., 1996
). In
brief, triplicate wells (from a 48-well plate) containing confluent-transfected COS cells were incubated with mAbs OKM10, 903, or TS1/18 (each
at 2 µg/ml), or biotinylated NIF (at 400 ng/ml) in Tris-NaCl buffer, pH 7.4, containing 1 mM MgCl2, 1 mM CaCl2, 1% BSA (TMB buffer), and 0.02%
sodium azide for 1 h at 4°C. Cells were then washed and incubated with
125I-labeled goat anti-mouse immunoglobulin (New England Nuclear, Boston, MA) (for mAbs) or with 125I-coupled avidin (Amersham, Arlington Heights, IL) (for NIF) under similar conditions. After washing, cells
were solubilized with 1% SDS, 0.2 N NaOH and the extracts were
counted. Specific binding was obtained by subtracting the background
binding to mock-transfected COS cells (usually <5% of total binding).
The binding data from three independent experiments were pooled and
expressed as histograms representing mean ± SEM, before the mutants
were decoded. Binding of mAbs and NIF to COS cells was normalized for
the percentage of binding obtained with WT as follows:% binding = (mutant binding/WT binding) × 100.
EiC3b binding was assessed by adding 40 µl of fluoresceinated EiC3b
in TMB buffer to triplicate confluent wells (from a 24-well plate) in a total
volume of 500 µl followed by a brief 15-s spin at 800 rpm/min. After a
5-min incubation at 37°C and two washes, the cells were solubilized with
1% SDS, 0.2 N NaOH and the fluorescence was quantified (excitatory
wavelength, 490 nm; emission wavelength, 510 nm) using a SLM 8000 fluorometer (SLM Instruments, Urbana, IL) (Michishita et al., 1993). Specific binding was obtained by subtracting background binding to mock-transfected COS cells. Binding was normalized to the percentage of binding obtained with WT.
Purified iC3b and fibrinogen were diluted to 50 µg/ml and 50 µl of each diluted protein was placed in triplicates at the well center of 24-well nontissue culture plates (Becton Dickinson). After incubating overnight at 4°C, the plates were washed and blocked with BSA. WT- or F302W-expressing CHO cells (106 in 400 µl of TMB buffer) were added to each well and incubated for 30 min at 37°C. After three washes, bound cells were quantified by detecting the cellular acid phosphatase level. Binding to Neo-transfected CHO cells was subtracted. Binding was normalized to the percentage of binding obtained with WT.
Flow Cytometry
WT-, F302W-, or Neo-transfected CHO cells were washed and resuspended in Ham's F12 nutrient mixture containing 2 mM MnCl2 and 0.5% BSA to 6 × 106/ml. To a 50-µl cell suspension, FITC-conjugated mAbs 7E3, 44 (Sigma), or mouse IgG1 (Sigma) were added to a final concentration of 20 µg/ml, and incubated for 20 min at room temperature. The cells were washed, pelleted, resuspended in PBS containing 1% formaldehyde, and then analyzed immediately on a Becton Dickinson FACScan® flow cytometer. The fraction of CR3 recognized by 7E3 (high affinity CR3) was expressed as a ratio of the mean fluorescence intensity (MFI) generated by 7E3 to that generated by mAb 44 (which recognizes the whole population of expressed CR3) as follows: high affinity CR3 (%) = (MFI of 7E3)/ (MFI of 44) × 100.
mAb and Ligand Binding to Purified WT and Mutant r11bA
This was carried out on three different WT and F302W r11bA preparations as described (Ueda et al., 1994) with the following modifications. 50 µl of PBS, pH 7.4, containing 2 µg of WT or mutant r11bA was placed in
triplicates in 96-well plates overnight at 4°C. Wells were washed, blocked
with BSA, and then used in mAb or ligand-binding assays. Reactivity of
r11bA with the anti-CD11b mAbs 44, 904, and 7E3 was assessed by incubating r11bA-containing wells with each mAb (10 µg/ml) for 1 h at room
temperature, followed by a washing step, and a second incubation with alkaline phosphatase-coupled secondary antibody (Sigma) for an additional
hour. Color reaction was then developed by adding 1 mg/ml p-nitrophenyl-phosphate, and quantified using a plate reader.
Binding of biotinylated EiC3b to immobilized WT or mutant r11bA
was carried out by incubating 3 × 106 EiC3b cells in 50 µl veronal buffered
saline, pH 7.4, containing 1 mM MgCl2, 1 mM CaCl2, and 0.1% gelatin, for
15 min at 37°C. After gentle washing, bound EiC3b were fixed with 1%
glutaraldehyde, blocked with BSA, and treated with streptavidin-alkaline
phosphatase conjugate and p-nitrophenyl-phosphate. Bound EiC3b was
quantified by measuring the absorbance at 405 nm. Binding of biotinylated NIF to immobilized WT and mutant r11bA was carried out as described (Rieu et al., 1994). Background binding (binding to metal-defective mutant D140GS/AGA) was subtracted.
BIAcoreTM Analysis
The apparent equilibrium constants for binding of three different preparations of WT and F302W r11bA to the complement fragment iC3b were
measured using surface plasmon resonance on a BIAcoreTM (BIAcore
AB, Uppsala, Sweden). The Biosensor device was used in accordance
with the manufacturer's instructions. In brief, iC3b was covalently coupled
via primary amine groups to the dextran matrix of a CM5 sensor chip
(BIAcore AB). BSA immobilized in the same way was used as a control
surface. The WT and F302W A-domain proteins were flowed over the
chip at 5 µl/min. TBS (20 mM Tris-HCl, pH 8.0, 150 mM NaCl) with 2 mM
MgCl2 and 0.005% P20 (BIAcore AB) was used as running buffer
throughout. 1 M NaCl in 20 mM Tris-HCl, pH 8.0, was used to remove the
bound proteins and to regenerate the surface for further binding experiments. The binding was measured as a function of time. The binding data
(after subtracting background binding to BSA-coated chip) were analyzed
using Scatchard plots as described (Dall'Acqua et al., 1996). For quantitatively determining the active proportion of the A-domain proteins, iC3b
(an activation-dependent ligand) and mAb 904 (an activation- and metal-independent ligand) were each immobilized on a CM5 sensor chip. The
WT and F302W A-domain proteins were flowed over the chip at 2 µl/min.
The initial binding rates (obtained from linear regression of binding data
over a 10-15-s period from the initial binding phase) under conditions of
mass transfer limitation are proportional to the active protein concentration and independent of receptor-ligand affinity (Karlsson et al., 1993
).
Two different amounts of ligand (6,300 and 8,000 RU for iC3b; 4,200 and
6,200 RU for 904) were first used to examine the mass transfer limiting
conditions. 100 mM HCl was used to regenerate the mAb 904 surface. The
higher ligand densities of iC3b and 904 were used to determine the active
proportion of the A-domain proteins.
![]() |
Results and Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Crystal Structure of the CD11b A-Domain in Complex with Mn2+
The structure of r11bA crystallized in the presence of
Mn2+ is nearly identical to that of the Mg2+ form (Lee et al.,
1995b). The bound manganese ion is located in a shallow
crevice at the top of the internal
sheet where it is coordinated by S142, S144, T209, and two water molecules. The
sixth Mn2+ coordination site is provided by the side chain
of E314 from a neighboring A-domain within the crystal
lattice (Fig. 1 A). These structures are referred to as
adopting the open conformation since F275 and F302
are solvent exposed (Fig. 1 C). The closed conformation
(burial of F302, F275, or their equivalents into the hydrophobic core of the protein, a break in the T209 [or
equivalent threonine]-metal bond; Fig. 1, B and D) and a
corresponding change in surface charge and topology of
MIDAS (Lee et al., 1995a,b; Qu and Leahy, 1995
; Qu and
Leahy, 1996
; Emsley et al., 1997
; Baldwin et al., 1998
) are
found in all remaining integrin A-domain structures determined to date. This includes the Mn2+ and no-metal forms
of CD11bA, Mn2+ and Mg2+ forms of CD11aA, and a
Mg2+-complexed form of CD49bA. Taken together, these
findings suggest that the integrin A-domain exists primarily in two conformations, the formation of which is unaffected by the nature of the metal ion in the active site or
the experimental conditions of protein purification and
crystal growth.
|
Mapping of the Binding Site for the Activation-dependent Ligand iC3b
We introduced single or double amino acid substitutions
in residues scattered in all 11 loops and adjacent helices of
the r11bA structure with the exception of the largely
hydrophobic C-
2 loop (H183FT) and the
2-
3 loop
(N192PNP) (where a P195A substitution had detrimental
effects on metal ion coordination; Michishita et al., 1993
).
All of the targeted residues had solvent-exposed side
chains (relative total side chain accessibility values ranged
from ~25 to 100%), and were replaced either with residues from CD11a (which does not bind to iC3b or NIF),
with residues having the opposite charge, or with alanines.
The WT and mutant receptors expressed in COS cells were then probed with mAbs or ligands as described
(Michishita et al., 1993
; Rieu et al., 1996
). None of the mutations affected the normal expression of the receptors as
judged by binding of the anti-CD11b mAbs OKM10 (Fig.
2 A), 903, and the anti-CD18 mAb TS1/18 (Rieu et al.,
1996
; and data not shown). Binding of G143M, D149K,
E178E/AA, T203Q/KH, R208L, F246K, and E278K/AA
receptors to iC3b was either absent or significantly reduced (Fig. 2 B), whereas that of E244K and D273K was
significantly increased. Gain-of-function mutations are not
unusual in contact regions of protein-protein complexes
(Clackson and Wells, 1995
). A smaller but still significant increase in binding of K166S/AA was also observed. None
of the remaining eight mutations (involving 11 amino acids) affected iC3b binding significantly. The loss of iC3b
binding to some mutants was not caused by defective formation of the heterodimer (Fig. 2 B, inset; Rieu et al.,
1996
) or an inability of the domain to bind metal: Mn54
bound directly to G143M, D149K, E178E/AA, and R208L
r11bA mutants, and the metal-dependent interaction of biotinylated NIF with the remaining mutants T203Q/KH,
E244K, F246K, D273K, and E278K/AA was normal (Rieu
et al., 1996
). With the exception of E278K and T203 (PQ
and K, respectively, in mouse), the residues involved in
iC3b binding were either identical (G143, D149, E179,
Q204, R208, E244, and F246) or conserved (E178 and
D273) in mouse CR3 (Pytela, 1988
). This may explain the
ability of mouse and human CR3 to bind to human and
mouse iC3b, respectively. The relative affinity of these
cross-species interactions has not been determined.
|
Previous studies have examined the structural basis of
CR3 binding to iC3b. One study focused on residues in the
D-
5 loop (F246-Y252) adjacent to D242 (McGuire and
Bajt, 1995
), since these residues are absent in the non-
iC3b-binding CD11a A-domain (Rieu et al., 1996
), and
peptides spanning this loop or immediately preceding it affect iC3b binding (Ueda et al., 1994
). Deletion of the
D-
5 loop in human CR3 or a D248A substitution abolished receptor binding to iC3b (McGuire and Bajt, 1995
). The
D-
5 loop was among those targeted in our mapping
study, and replacement of one of its residues F246 with
lysine (F246K) abolished iC3b binding, whereas G247A
and P249A substitutions had no effect (Fig. 2 B). An
F246A substitution also reduced iC3b binding, although less dramatically than the F246K substitution (McGuire
and Bajt, 1995
). We have not included D248 and Y252 in
our mutagenic approach since the respective side chains
are not solvent-exposed (relative total side chain accessibility values were 0 and ~10%, respectively, in either
conformation). Detrimental structural effects might have
caused the defective binding of these mutants to iC3b.
Supportive evidence is provided by the finding that deletion of D248-Y252 led to the loss of CR3 binding to three
different metal-dependent ligands including NIF (Zhang
and Plow, 1996b
). The present data reveal that residues
from five different loops and two of their connecting helices contribute to the iC3b-binding site in r11bA.
The iC3b-binding Site Is Located on the MIDAS Face and Involves Conformationally Sensitive Residues
The residues involved in iC3b binding mapped to the MIDAS face of r11bA, in close proximity to the metal ion
(Fig. 3). Two other ligands, NIF and CD54, also require
residues expressed on the MIDAS face for interaction
with CD11b and CD11a receptors, respectively (Rieu et al.,
1994; Huang and Springer, 1995
). The divalent cation-
dependent interaction of iC3b with CR3 or its isolated
r11bA requires key glutamate residues in iC3b (Taniguchi-Sidle and Isenman, 1994
). The ring-like arrangement
of the iC3b-binding site around the metal ion lends support to our hypothesis that the exogenous metal-coordinating glutamate in the open structure may be a mimic
of an integrin interaction with ligand (Lee et al., 1995b
).
Recent docking of collagen and CD54 ligands on the A-domains of CD49b and CD11a, respectively, showed
that the respective glutamates can be accommodated in
the A-domain without severe steric clashes, suggesting
that the metal ion in the A-domain can coordinate the
glutamate "ligands" directly (Emsley et al., 1997
; Bella et
al., 1998
). Co-crystals of the A-domain in complex with activation-dependent and -independent ligands will be required to determine if the metal ion contributes directly to
ligand coordination.
|
|
The residues G143, D149, R208, and E178E that are
shared by the binding sites for iC3b and NIF (an activation-independent ligand) are located on one side of the
metal ion (Fig. 3). Interestingly, the relative position of
these residues in relation to the metal ion changed little
(the C-metal ion distances generally
1 Å) in the open
and closed conformations (Table II). In contrast, the relative position of most of the residues which selectively affect iC3b binding changed significantly in the two conformations with respect to the metal ion (C
-metal ion
distances changed by several angstroms in some cases)
(Table II). Thus, a major distinguishing feature between
the open and closed conformations, namely the change in
topology on the MIDAS face, may be relevant to the activation-dependent binding of CR3 to iC3b. Conformational changes on the MIDAS face may be required to develop an optimal binding interface between CR3 and its
physiologic ligands.
Effects of F302W or F275R Substitutions on Receptor Binding to iC3b, NIF, and mAb 7E3
A second structural difference between the open and closed r11bA conformations is a major increase in the solvent accessibility of the conserved F302 and F275 in the open conformation (relative total side chain accessibility values increase from 6.4 to 81.5% for F302 and from 0.3 and 26.4% for F275). Therefore, we assessed the effects of introducing bulky or charged side chains at these positions on the activation-dependent interaction of CR3 with iC3b. F302 was replaced with arginine, tryptophan, or tyrosine (as a control), and F275 was replaced with arginine. The CR3 mutant F302R was not expressed on the cell surface (data not shown). The remaining mutants were surface expressed in normal quantities relative to the WT receptor (Fig. 4 A). To determine the functional profile of the resulting mutants, the recombinant receptors were probed with the activation-dependent and -independent ligands iC3b and NIF, respectively. Whereas the binding of iC3b to the conserved F302Y receptor was indistinguishable from that of WT, iC3b binding to F302W and F275R was significantly increased (Fig. 4 B). On the other hand, NIF bound equally to F302Y, F302W, and F275R receptors. Similar observations were obtained in stable CHO cell lines expressing comparable amounts of WT or F302W (Fig. 4 C). Increased binding of F302W was not limited to iC3b, but also occurred with fibrinogen, another activation-dependent ligand (Fig. 4 C).
|
The 11bA recognizing mAb 7E3 (Zhou et al., 1994) is a
ligand-mimetic antibody whose binding to the holoreceptor in leukocytes or in cells transfected with recombinant
CR3 is stimulated by the same agonists that trigger physiologic ligand binding (Altieri and Edgington, 1988
; Altieri,
1991
; Simon et al., 1997
). 7E3 is thus very useful in detecting high affinity CR3 in intact cells. The estimate of the
later species is ~10% when 7E3 or a second ligand mimetic mAb CBRM1/5 (Diamond and Springer, 1993
; Simon et al., 1997
) is used. To assess the impact of the
F302W modification on affinity modulation in CR3, we
compared the binding of 7E3 to CHO cells expressing WT
or F302W CR3. In six independent experiments (one of
which is shown in Fig. 5), we found that the fraction of
CR3 recognized by 7E3 was 5.95 ± 1.6% of total CR3 for
WT and 14.9 ± 3.47% for F302W. Thus the F302W substitution increases the fraction of high affinity CR3 in whole
cells. Increased binding of iC3b and 7E3 to F302W r11bA
was also observed (Fig. 6), whereas binding of NIF was unchanged. Taken together, the above findings indicate that
a conformational change intrinsic to the A-domain enhances the binding of the holoreceptor as well as the isolated A-domain to activation-dependent ligands. Since
7E3 is a marker of the high affinity state, the observed increase in receptor binding appears to largely result from a
change in receptor affinity.
|
|
Binding Properties of the T209A Receptor
The third major distinguishing feature between the two
r11bA conformations is the shift in metal coordination
from a direct coordination of T209 with the metal in the
open form to a break in T209-metal bond in the closed
form (Fig. 1). We assessed the functional significance of
this shift on metal binding and receptor activation. We
first reasoned that if the two Mn2+-containing structures
have biologic relevance, then a T209A mutation should
not compromise the ability of r11bA to bind the metal ion. This was in fact the case: the normally expressed (Fig. 4 A)
and heterodimeric (Kamata et al., 1995b; and data not
shown) T209A CR3 bound normally to the activation-independent ligand NIF (Fig. 4 B). Since NIF binding requires divalent cations and an intact MIDAS (the metal-defective CR3 mutants D140GS/AGA or D242A do not
bind to NIF [Rieu et al., 1994
]), this finding indicates that the T209A CR3 can coordinate the metal ion in the MIDAS site. We then assessed the effect of T209A on receptor activation as quantified by binding to iC3b. As shown
in Fig. 4 B, T209A receptor did not bind to iC3b in the
presence of divalent cations. Similar results were obtained
when binding of NIF and iC3b to the isolated T209A
A-domain was carried out (Fig. 6). Interestingly, introducing the F302W mutation in T209A failed to restore any
binding of the double mutant to iC3b (Fig. 4 B). A previous study (Kamata et al., 1995b
) showed that a T209A mutation in the holoreceptor abolished its ability to bind to
another activation-dependent ligand CD54, but suggested
that this was caused by loss of metal coordination. The
present findings clearly show an intact metal coordination site in the T209A mutant as judged by the normal binding
of NIF. Therefore, these data suggest that direct coordination of the metal ion by T209 (as in the open conformation) is a necessary feature of the activated state. Switching this coordination from T209 to D242 as in the closed
conformer generates an inactive receptor. Taken together,
the above data show that all three features of the open
conformation (the change in the topology of the MIDAS face, the solvent accessibility of side chains at positions 302 and 275, and the direct coordination of the metal by T209)
are relevant to enhancing CR3 or r11bA binding to activation-dependent ligands, suggesting a functional significance for these linked structural features.
Two Functional States for the A-Domain Exist in Solution: Effect of the F302W Mutation on the Active State
A simple model that explains the above functional and
structural studies is that the isolated r11bA exists in two
functional states in solution, one active (defined by its ability to bind to activation-dependent ligands) and the other
inactive (although still able to bind certain antagonists
such as NIF). Activating mutations (such as F302W) or inactivating mutations (such as T209A) change the relative
abundance of these two states. To test this model, we used
surface plasmon resonance (Malmqvist, 1993) and examined the binding of WT and F302W r11bA to iC3b and
mAb 904, an activation-independent and metal-independent ligand. When 1 µM of WT and F302W was injected
onto the BIAcoreTM sensor chip coupled to excess iC3b, an
approximately twofold increase in binding of F302W was
observed compared with WT (Fig. 7 A), in agreement with
the other binding data presented in Figs. 4-6. When the
same amounts of WT and F302W were injected onto the
mAb 904-coupled chip surface, no difference in the binding level was found (Fig. 7 B). This indicates that equivalent amounts of WT and F302W r11bA were available for
binding. Injection of increasing concentrations of the WT
r11bA ranging from 0.5 to 15 µM at a flow rate of 5 µl/min
gave a saturable binding curve (Fig. 8, A and C). Scatchard plot of the binding data was linear, with a dissociation constant Kd of 3.8 µM (Fig. 8 C). A similar analysis using
F302W revealed an almost identical affinity (Fig. 8, B and
D). The observed ligand-binding affinity was significantly
lower than that reported for binding of purified CR3 to
ligands (Kd ~12.5-200 nM) (Berman et al., 1993
; Cai and
Wright, 1995
). One interpretation for this difference is
that the A-domain preparation contains only a subpopulation of active species. Biosensor technology can be used to
measure the active analyte in a protein preparation under
conditions where binding to ligand (present in excess) is
only limited by the diffusion of the analyte to the surface-bound ligand. Under these conditions, initial binding rates
are proportional to the active analyte concentration and
independent of the analyte-ligand affinity. This can be validated experimentally by demonstrating that the initial
binding rate is independent of ligand density (Karlsson
et al., 1993
). We used mAb 904 in parallel in order to estimate total binding. By decreasing the flow rate and increasing the ligand density, the binding rate of WT and
F302W r11bA to chips coated with iC3b or mAb 904 can be made independent of the respective ligand density (Table III) and therefore a function of the concentration of
the binding active species. In WT, this active species represented ~11 ± 1.7% of the total r11bA (Table IV). In parallel experiments, we showed that the proportion of the
active species in F302W increased by ~2.5-fold (25 ± 1.1%). The fact that a major portion of F302W remains in
the inactive state probably reflects other structural considerations that allow motion of the
7 helix to that of the closed form, despite a partial burial of the side chain at position 302. The recent structure of the CD49b A-domain
shows that this does in fact occur: the orientation of the
7
helix is very similar to that in the closed form of r11bA,
despite only a partial burial of the side chain of E318
(equivalent to F302) at the top of the
7 helix (Emsley et
al., 1997
). Since, the total amount of r11bA was used in
calculating the binding affinities shown in Fig. 8, the affinity of the active species should be ~10-fold higher, approaching that calculated for purified CR3 and of the active cell-bound form of CD11a/CD18 (Lollo et al., 1993
).
|
|
|
|
In summary, the r11bA exists in two functional states in
solution as assessed by BIAcoreTM. These two forms are
equally capable of interacting with activation-independent
ligands such as NIF, but display marked differences in
their affinity to physiologic ligands such as iC3b, fibrinogen, and the ligand mimetic mAb 7E3. The two states appear to be in a dynamic equilibrium with a majority of the
domain in an inactive state (defined as one incapable of binding to activation-dependent ligands, due to the lack of
an activation-specific ligand-binding interface). This equilibrium can be modulated both positively or negatively by
certain mutations (described in this report) and perhaps
by others (Zhang and Plow, 1996a). Based on the functional analysis of the various A-domain mutants, we also
suggest that the active and inactive states may correspond
to the open and closed structures, respectively. In this
scenario, analogous movement of the COOH-terminal
7
helix of the A-domain in the holoreceptor switches the receptor to its active state. Since a MIDAS-like ligand-binding motif is present in all
subunits, an affinity switch not
unlike that of G proteins may be operational on the extracellular face in all integrins.
![]() |
Footnotes |
---|
Address correspondence to M. Amin Arnaout, M.D., Renal Unit, Massachusetts General Hospital and Harvard Medical School, 149 13th Street, 8th Floor, Charlestown, MA 02129. Tel.: (617) 726-5663. Fax: (617) 726-5669. E-mail: arnaout{at}receptor.mgh.harvard.edu
Received for publication 14 May 1998 and in revised form 4 September 1998.
Grants from the National Institutes of Health and a fellowship grant
from the American Heart Association and the Philippe Foundation supported this work. The Brookhaven National Light Source Facility is supported by the US Department of Energy, Office of Health and Environmental Research, and by the National Science Foundation.
We thank Drs. Shu-Ichi Kanazachi for protein purification; George Chen and Takashi Sugimori for plasmid constructs; Alain Viel, Ben Madden, Andrew Tyler, and Ashok Khatri for assistance in protein characterization; and Lonny Berman and his staff at beamline X25 of the Brookhaven National Light Source for assistance in data collection.
![]() |
Abbreviations used in this paper |
---|
MFI, mean fluorescence intensity; MIDAS, metal ion-dependent adhesion site; NIF, neutrophil inhibitory factor; WT, wild-type.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. |
Altieri, D.C..
1991.
Occupancy of CD11b/CD18 (Mac-1) divalent ion binding
site(s) induces leukocyte adhesion.
J. Immunol.
147:
1891-1896
|
2. |
Altieri, D.C., and
T.S. Edgington.
1988.
The saturable high affinity association
of factor X to ADP-stimulated monocytes defines a novel function of the
MAC-1 receptor.
J. Biol. Chem.
263:
7007-7015
|
3. |
Andrew, D.P.,
C. Berlin,
S. Honda,
T. Yoshino,
A. Hamann,
B. Holzmann,
P.J. Kilshaw, and
E.C. Butcher.
1994.
Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation.
J. Immunol.
153:
3847-3861
|
4. | Arnaout, M.A., R.F. Todd III, N. Dana, J. Melamed, S.F. Schlossman, and H.R. Colten. 1983. Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of iC3b binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mo1). J. Clin. Invest. 72: 171-179 |
5. |
Bajt, M.L., and
J.C. Loftus.
1994.
Mutation of a ligand binding domain of ![]() ![]() ![]() |
6. | Baldwin, E.T., R.W. Sarver, G.L. Bryant, K.A. Curry, M.B. Fairbanks, B.C. Finzel, R.L. Garlick, R.L. Heinrikson, N.C. Horton, L.-L.C. Kelley, et al . 1998. Cation binding to CD11b I domain and activation model assessment. Structure. 6: 923-935 |
7. |
Bella, J.,
P.R. Kolatkar,
C.W. Marlor,
J.M. Greve, and
M.G. Rossmann.
1998.
The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin
ligand.
Proc. Natl. Acad. Sci. USA.
95:
4140-4145
|
8. | Berman, P.W., G. Nakamura, L. Riddle, H. Chiu, K. Fisher, M. Champe, A. Gray, and S. Fong. 1993. Biosynthesis and function of membrane bound and secreted forms of recombinant Mac-1. J. Cell Biochem. 52: 183-195 |
9. |
Bilsland, C.A.G.,
M.S. Diamond, and
T.A. Springer.
1994.
The leukocyte integrin p150,95 (Cd11c/CD18) as a receptor for iC3b.
J. Immunol.
152:
4582-4589
|
10. |
Cai, T.Q., and
S.D. Wright.
1995.
Energetics of leukocyte integrin activation.
J.
Biol. Chem.
270:
14358-14365
|
11. | Clackson, T., and J.A. Wells. 1995. A hot spot of binding energy in a hormone-receptor interface. Science. 267: 383-386 |
12. | Coller, B.S.. 1985. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Invest. 76: 101 |
13. | D'Souza, S.E., M.H. Ginsberg, T.A. Burke, S.C.-T. Lam, and E.F. Plow. 1988. Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science. 242: 91-93 |
14. | D'Souza, S.E., T.A. Haas, R.S. Piotrowicz, W.V. Byers, D.E. McGrath, H.R. Soule, C. Cierniewski, E.F. Plow, and J.W. Smith. 1994. Ligand and cation binding are dual functions of a discrete segment of the integrin beta 3 subunit: cation displacement is involved in ligand binding. Cell. 79: 659-667 |
15. | Dall'Acqua, W., E.R. Goldman, E. Eisenstein, and R.A. Mariuzza. 1996. A mutational analysis of the binding of two different proteins to the same antibody. Biochemistry. 35: 9667-9676 |
16. |
Dana, N.,
B. Styrt,
G.D. Griffin,
R.F. Todd III,
M.S. Klempner, and
M.A. Arnaout.
1986.
Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies.
J. Immunol.
137:
3259-3263
|
17. | Deng, W.P., and J.A. Nicoloff. 1992. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. Anal. Biochem. 200: 81-88 |
18. | Diamond, M.S., and T.A. Springer. 1993. A subpopulation of Mac-1 (CD11b/ CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J. Cell Biol. 120: 545-556 [Abstract]. |
19. | Diamond, M.S., J. Garcia-Aguilar, J.K. Bickford, A.L. Corbi, and T.A. Springer. 1993. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J. Cell Biol. 120: 1031-1043 [Abstract]. |
20. | Dransfield, I., C. Cabanas, J. Barrett, and N. Hogg. 1992. Interaction of leukocyte integrins with ligand is necessary but not sufficient for function. J. Cell Biol. 116: 1527-1535 [Abstract]. |
21. |
Du, X.,
M. Gu,
J.W. Weiel,
C. Nagaswami,
J. Bennet,
R. Bowdicth, and
M.H. Ginsberg.
1993.
Long range propagation of conformational changes in integrin aIIbb3.
J. Biol. Chem.
268:
23087-23092
|
22. |
Emsley, J.,
S.L. King,
J.M. Bergelson, and
R.C. Liddington.
1997.
Crystal structure of the I domain from integrin alpha2beta1.
J. Biol. Chem.
272:
28512-28517
|
23. | Finzel, B.C.. 1987. Incorporation of fast Fourier transforms to speed restrained least-squares refinement of protein structures. J. Appl. Crystalog. 20: 53-55 . |
24. |
Golenbock, D.T.,
Y. Liu,
F.H. Millham,
M.W. Freeman, and
R.A. Zoeller.
1993.
Surface expression of human CD14 in Chinese hamster ovary fibroblasts imparts macrophage-like responsiveness to bacterial endotoxin.
J.
Biol. Chem.
268:
22055-22059
|
25. |
Huang, C., and
T.A. Springer.
1995.
A binding interface on the I domain of
lymphocyte function-associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1).
J. Biol. Chem.
270:
19008-19016
|
26. | Hynes, R.O.. 1992. Integrins: versatility, modulation and signaling in cell adhesion. Cell. 69: 11-26 |
27. |
Kamata, T., and
Y. Takada.
1994.
Direct binding of collagen to the I domain of
integrin ![]() ![]() |
28. |
Kamata, T.,
W. Puzon, and
Y. Takada.
1995a.
Identification of putative ligand-binding sites of the integrin ![]() ![]() |
29. | Kamata, T., R. Wright, and Y. Takada. 1995b. Critical threonine and aspartic acid residues within the I domains of beta 2 integrins for interactions with intercellular adhesion molecule 1 (ICAM-1) and C3bi. J. Biol. Chem. 2705: 12531-12535 . |
30. | Karlsson, R., L. Fagerstam, H. Nilshans, and B. Persson. 1993. Analysis of active antibody concentration. Separation of affinity and concentration parameters. J. Immunol. Methods. 166: 75-84 |
31. | Kunkel, T.A., J.D. Roberts, and R.A. Zakour. 1987. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154: 367-382 |
32. | Laemmli, U.K.. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227: 680-685 |
33. | Landis, R.C., R.I. Bennett, and N. Hogg. 1993. A novel LFA-1 activation epitope maps to the I domain. J. Cell Biol. 120: 1519-1527 [Abstract]. |
34. | Landis, R.C., A. McDowall, C.L. Holness, A.J. Littler, D.L. Simmons, and N. Hogg. 1994. Involvement of the "I" domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3. J. Cell Biol. 126: 529-537 [Abstract]. |
35. | Lee, J.-O., L. Anne-Bankston, M.A. Arnaout, and R.C. Liddington. 1995a. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure. 3: 1333-1340 |
36. |
Lee, J.-O.,
P. Rieu,
M.A. Arnaout, and
R. Liddington.
1995b.
Crystal structure
of the A-domain from the ![]() ![]() |
37. |
Lollo, B.A.,
K.W.H. Chan,
E.M. Hanson,
V.T. Moy, and
A.A. Brian.
1993.
Direct evidence for two affinity states for lymphocyte function-associated antigen 1 on activated T cells.
J. Biol. Chem.
268:
21693-21700
|
38. | Malmqvist, M.. 1993. Biospecific interaction analysis using biosensor technology. Nature. 361: 186-187 |
39. | Maniatis, T., E.F. Fritch, and J. Sambrook. 1989. Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. |
40. |
McGuire, S.L., and
M.L. Bajt.
1995.
Distinct ligand binding sites in the I domain
of integrin alpha M beta 2 that differentially affect a divalent cation-dependent conformation.
J. Biol. Chem.
270:
25866-25871
|
41. |
Michishita, M.,
V. Videm, and
M.A. Arnaout.
1993.
A novel divalent cation-binding site in the A domain of the ![]() |
42. | Otwinowski, Z. 1991. Maximum likelihood refinement of heavy atom parameters. In Isomorphous Replacement and Anomalous Scattering. W. Wolf, P.R. Evans, and A.G.W. Leslie, editors. Science and Engineering Research Council, Darensbury Laboratory. 80-86. |
43. |
Pytela, R..
1988.
Amino acid sequence of murine Mac-l![]() |
44. |
Qu, A., and
D.J. Leahy.
1995.
Crystal structure of the I-domain from the
CD11a/CD18 (LFA-1, ![]() ![]() |
45. | Qu, A., and D.J. Leahy. 1996. The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin. Structure. 4: 931-942 |
46. |
Randi, A.M., and
N. Hogg.
1994.
I domain of ![]() |
47. |
Rieu, P.,
T. Sugimori,
D.L. Griffith, and
M.A. Arnaout.
1996.
Solvent accessible
residues on the MIDAS face of integrin CR3 mediate its binding to the neutrophil adhesion inhibitor NIF.
J. Biol. Chem.
271:
15858-15861
|
48. |
Rieu, P.,
T. Ueda,
I. Haruta,
C.P. Sharma, and
M.A. Arnaout.
1994.
The
A-domain of ![]() |
49. | Ross, G.D., J.A. Cain, B.L. Myones, S.L. Newman, and P.J. Lachmann. 1987. Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement. 4: 61-74 |
50. | Sanger, F., S. Nicklen, and A.R. Coulson. 1977. DNA sequencing with chain terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74: 5463-5467 [Abstract]. |
51. |
Simon, D.I.,
H. Xu,
S. Ortlepp,
C. Rogers, and
N.K. Rao.
1997.
7E3 monoclonal
antibody directed against platelet glycoprotein IIb/IIIa cross-reacts with the
leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.
Arterioscler. Thromb. Vasc. Biol.
17:
528-535
|
52. |
Smith, J.W., and
D.A. Cheresh.
1988.
The Arg-Gly-Asp binding domain of the
vitronectin receptor.
J. Biol. Chem.
263:
18726-18731
|
53. |
Taniguchi-Sidle, A., and
D.E. Isenman.
1994.
Interactions of human complement component C3 with factor B and with complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) involve an acidic sequence at
the N-terminus of C3 alpha-chain.
J. Immunol.
153:
5285-5302
|
54. |
Tuckwell, D.,
D.A. Calderwood,
L.J. Green, and
M.J. Humphries.
1995.
Integrin ![]() |
55. |
Ueda, T.,
P. Rieu,
J. Brayer, and
M.A. Arnaout.
1994.
Identification of the
complement iC3b binding site in the ![]() |
56. | Wright, S.D., P.A. Reddy, M.T.C. Jong, and B.W. Erickson. 1987. C3bi receptor (complement receptor type 3) recognizes a region of complement protein C3 containing the sequence arg-gly-asp. Proc. Natl. Acad. Sci. USA. 84: 1965-1968 [Abstract]. |
57. | Xie, J., R. Li, P. Kotovuori, C. Vermot-Desroches, J. Wijdenes, M.A. Arnaout, P. Nortamo, and C.G. Gahmberg. 1995. Intercellular adhesion molecule-2 (CD102) binds to the leukocyte integrin CD11b/CD18 through the A domain. J. Immunol. 155: 3619-3628 [Abstract]. |
58. |
Zhang, L., and
E.F. Plow.
1996a.
A discrete site modulates activation of I domains.
J. Biol. Chem.
271:
29953-29957
|
59. |
Zhang, L., and
E.F. Plow.
1996b.
Overlapping, but not identical sites are involved in the recognition of C3bi, neutrophil inhibitory factor, and adhesive
ligands by the ![]() ![]() |
60. |
Zhou, L.,
D.H. Lee,
J. Plescia,
C.Y. Lau, and
D.C. Altieri.
1994.
Differential
ligand binding specificities of recombinant CD11b/CD18 integrin I-domain.
J. Biol. Chem.
269:
17075-17079
|